Shreya Healthcare managing director Amol Shah said that the Rs 27-crore Taloja facility is backed by ``technical support'' from Eli Lilly and can manufacture up to eight million vials of Humulin and 10 million vials of Kefzol on a single shift (of eight hours) basis.

While the cephalosporins unit is already on stream, phase two--which involves production of liquid injectables--would go on stream before the end of this month. The Taloja facility employs roughly 75 people and is on course to seeking the approval of the Medicines Control Agency (MCA), the UK. The process and layout at the plant have been designed in consultation with Eli Lilly International's technical services supportgroup.

Shreya Healthcare expects to achieve an export turnover of around Rs 60-70 crore in the first year of operation, while the domestic operations should yield sales of Rs 30 crore by the third year.

Shah also said that a full-fledged national field force, comprising around 300 personnel, would be in place over the next three years, even as the company is in talks with overseas players for in-licensing alliances.

The company's dedicated research and development facility would focus on novel drug delivery systems (NDDS) and generics and Shreya is already in talks with a UK-based organisation for possible joint development efforts.

Shreya Healthcare is promoted by Sujit Kumar Singh and Amol Shah, the erstwhile owner of MJ Pharmaceuticals and has an initial equity capital of Rs 6 crore. This would go up to Rs 8 crore, by way of issue of preference capital, in due course.